Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.
Fiche publication
Date publication
août 2020
Journal
Stem cells translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle
Tous les auteurs :
Laroye C, Gibot S, Huselstein C, Bensoussan D
Lien Pubmed
Résumé
Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS-CoV-2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently tested and among them, mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in few clinical trials appear well-tolerated, promising, but many questions remain unanswered.
Mots clés
COVID-19, Wharton's Jelly, acute respiratory distress syndrome, mesenchymal stromal/stem cells, sepsis
Référence
Stem Cells Transl Med. 2020 Aug 18;: